MetaCap

Kailera Therapeutics (KLRA) vs Precigen (PGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Precigen is the larger company by market cap ($1.51 billion vs $1.43 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KLRA-57.62%PGEN+5.78%
+124%+27%-70%
Apr 17, 20261 yearNov 20, 2026
KLRA-57.62%PGEN+5.78%
+123%+27%-69%
Apr 13, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KLRA versus PGEN key metrics
MetricKLRAPGEN
Share price$11.02$4.21
Market cap$1.43B$1.51B
1-day change-4.84%+1.20%
YTD return—+0.72%
1-year return—+8.51%
5-year return—+9.07%
P/E ratio (TTM)—38.27
EPS (TTM)$-4.16$0.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$9.68M
Revenue growth (YoY)—+146.73%
Net income (latest FY)—$-250.64M
Operating margin—-1141.13%
Net margin—-2588.21%
52-week high$28.23$8.98
52-week low$9.76$3.04
Distance from 52-week high-60.96%-53.12%
Analyst consensusstrong_buybuy
Avg. price target upside+290.20%+224.70%
Average volume1.08M5.68M
Shares outstanding129.85M358.55M
Employees145160
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Kailera Therapeutics

KLRA stock →

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees

About Precigen

PGEN stock →

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees

KLRA vs PGEN FAQ

Which is bigger, Kailera Therapeutics or Precigen?

Precigen (PGEN) is larger, with a market capitalization of $1.51B compared with $1.43B for Kailera Therapeutics (KLRA).

Are Kailera Therapeutics and Precigen in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons